Immunological follow-up of patients with renal transplants: A proposal for clinical practice in Colombia
Abstract
Graft damage is a process that starts at the moment of transplantation, due to comorbidities of receptor, donor status, ischemia time, ischemia-reperfusion phenomenon, among others, those induce metabolic and immune factors that ultimately trigger clinical manifestations of graft dysfunction. However, the preclinical progression between the time of transplantation and the appearance of signs and symptoms of graft damage can take weeks to years.
Therefore, the implementation of rational monitoring approaches during the post-transplantation period is critical and should include not only the clinical follow-up but also anticipate immunological graft damage. In the present essay, we propose an immunological monitoring algorithm for the post-renal transplantation period.
Downloads
References
Sá H, Leal R, Rosa MS. Renal transplant immunology in the last 20 years: A revolution towards graft and patient survival improvement. Int Rev Immunol. 2017;36:182-203. https://doi.org/10.1080/08830185.2016.1225300
Locke JE, Zachary AA, Warren DS, Segev DL, Houp JA, Montgomery RA, et al. Proinflammatory events are associated with significant increases in breadth and strength of HLA-specific antibody. Am J Transplant. 2009;9:2136-9. https://doi.org/10.1111/j.1600-6143.2009.02764.x
Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D, et al. The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2018;18:293-307. https://doi.org/10.1111/ajt.14625
Djamali A, Kaufman DB, Ellis TM, Zhong W, Matas A, Samaniego M. Diagnosis and management of antibody-mediated rejection: Current status and novel approaches. Am J Transplant. 2014;14:255-71. https://doi.org/10.1111/ajt.12589
Gosset C, Viglietti D, Rabant M, Vérine J, Aubert O, Glotz D, et al. Circulating donor-specific anti-HLA antibodies are a major factor in premature and accelerated allograft fibrosis. Kidney Int. 2017;92:729-42. https://doi.org/10.1016/j.kint.2017.03.033
Cioni M, Nocera A, Innocente A, Tagliamacco A, Trivelli A, Basso S, et al. De novo donorspecific HLA antibodies developing early or late after transplant are associated with the same risk of graft damage and loss in nonsensitized kidney recipients. J Immunol Res. 2017;2017:1747030. https://doi.org/10.1155/2017/1747030
Mengel M, Sis B, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff 2011 meeting report: New concepts in antibody-mediated rejection. Am J Transplant. 2012;12:563-70. https://doi.org/10.1111/j.1600-6143.2011.03926.x
Colvin RB, Smith RN. Antibody-mediated organ-allograft rejection. Nat Rev Immunol. 2005;5:807-17. https://doi.org/10.1038/nri1702
Wiebe C, Gibson IW, Blydt-Hansen TD, Karpinski M, Ho J, Storsley LJ, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant. 2012;12:1157-67. https://doi.org/10.1111/j.1600-6143.2012.04013.x
Sis B, Halloran PF. Endothelial transcripts uncover a previously unknown phenotype: C4dnegative antibody-mediated rejection. Curr Opin Organ Transplant. 2010;15:42-8. https://doi.org/10.1097/MOT.0b013e3283352a50
Wiebe C, Gibson IW, Blydt-Hansen TD, Pochinco D, Birk PE, Ho J, et al. Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donorspecific antibody. Am J Transplant. 2015;15:2921-30. https://doi.org/10.1111/ajt.13347
Hidalgo LG, Campbell PM, Sis B, Einecke G, Mengel M, Chang J, et al. De novo donorspecific antibody at the time of kidney transplant biopsy associates with microvascular pathology and late graft failure. Am J Transplant. 2009;9:2532-41. https://doi.org/10.1111/j.1600-6143.2009.02800.x
Racusen LC, Haas M. Antibody-mediated rejection in renal allografts: Lessons from pathology. Clin J Am Soc Nephrol. 2006;1:415-20. https://doi.org/10.2215/CJN.01881105
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff 2013 meeting report: Inclusion of C4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14: 272-83. https://doi.org/10.1111/ajt.12590
Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FHJ, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and Non-HLA antibodies in transplantation. Transplantation. 2013;95:19-47. https://doi.org/10.1097/TP.0b013e31827a19cc
Bestard O, Cravedi P. Monitoring alloimmune response in kidney transplantation. J Nephrol. 2017;30:187-200. https://doi.org/10.1007/s40620-016-0320-7
Billen EVA, Christiaans MHL, Lee J, van den Berg-Loonen EM. Donor-directed HLA antibodies before and after transplantectomy detected by the luminex single antigen assay. Transplantation. 2009;87:563-9. https://doi.org/10.1097/TP.0b013e3181949e37
Huber L, Lachmann N, Niemann M, Naik M, Liefeldt L, Glander P, et al. Pretransplant virtual PRA and long-term outcomes of kidney transplant recipients. Transpl Int. 2015;28:710-9. https://doi.org/10.1111/tri.12533
Ercilla MG, Martorell J. Estudio inmunológico de la pareja donante-receptor. Nefrología. 2010;30:60-70. https://doi.org/10.3265/Nefrologia.pre2010.Nov.10692
Tambur AR, Campbell P, Claas FH, Feng S, Gebel HM, Jackson AM, et al. Sensitization in transplantation: Assessment of Risk (STAR) 2017 Working Group Meeting Report. Am J Transplant. 2018;18:1604-14. https://doi.org/10.1111/ajt.14752
Crespo E, Bestard O. Biomarkers to assess donor-reactive T-cell responses in kidney transplant patients. Clin Biochem. 2016;49:329-37. https://doi.org/10.1016/j.clinbiochem.2015.08.010
Grenzi PC, Campos ÉF, Silva HT, Felipe CR, Franco MF, Soares MF, et al. Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation. Transpl Immunol. 2015;32:61-5. https://doi.org/10.1016/j.trim.2015.02.004
Süsal C, Fichtner A, Tönshoff B, Mehrabi A, Zeier M, Morath C. Clinical relevance of HLA antibodies in kidney transplantation: Recent data from the Heidelberg Transplant Center and the Collaborative Transplant Study. J Immunol Res. 2017;2017:5619402. https://doi.org/10.1155/2017/5619402
Aubert O, Loupy A, Hidalgo L, van Huyen JPD, Higgins S, Viglietti D, et al. Antibody-mediated rejection due to preexisting versus de novo donor-specific antibodies in kidney allograft recipients. J Am Soc Nephrol. 2017;28:1912-23. https://doi.org/10.1681/ASN.2016070797
Mehra NK, Baranwal AK. Clinical and immunological relevance of antibodies in solid organ transplantation. Int J Immunogenet. 2016;43:351-68. https://doi.org/10.1111/iji.12294
Morath C, Opelz G, Zeier M, Süsal C. Clinical relevance of HLA antibody monitoring after kidney transplantation. J Immunol Res. 2014;2014:845040. https://doi.org/10.1155/2014/845040
Halloran PF, De Freitas DG, Einecke G, Famulski KS, Hidalgo LG, Mengel M, et al. The molecular phenotype of kidney transplants: Personal viewpoint. Am J Transplant. 2010;10:2215-22. https://doi.org/10.1111/j.1600-6143.2010.03267.x
Roedder S, Sigdel T, Salomonis N, Hsieh S, Dai H, Bestard O, et al. The kSORT assay to detect renal transplant patients at high risk for acute rejection: Results of the multicenter AART Study. PLoS Med. 2014;11. https://doi.org/10.1371/journal.pmed.1001759
Zhang Q, Reed EF. The importance of non-HLA antibodies in transplantation. Nat Rev Nephrol. 2016;12:484-95. https://doi.org/10.1038/nrneph.2016.88
Pearl MH, Zhang Q, Palma-Diaz MF, Grotts J, Rossetti M, Elashoff D, et al. Angiotensin II type 1 receptor antibodies are associated with inflammatory cytokines and poor clinical outcomes in pediatric kidney transplantation. Kidney Int. 2018;93:260-9. https://doi.org/10.1016/j.kint.2017.06.034
Some similar items:
- Paula Ximena Pavía, Nubia Lucía Roa, Ana María Uribe, Concepción Judith Puerta, Using S35-S36 and TcH2AF-R primer-based PCR tests to follow-up a Chagas’ disease patient who had undergone a heart transplant , Biomedica: Vol. 31 No. 2 (2011)
- John F. Arboleda, Luis F. García, Cristiam M. Álvarez, ILT3+/ILT4+ tolerogenic dendritic cells and their influence on allograft survival , Biomedica: Vol. 31 No. 2 (2011)
- Mario García, Liliana Alejandra Chicaíza, Hoover Quitián, Adriana Linares, Óscar Ramírez, Cost-effectiveness of consolidation treatments for acute myeloid leukemia in high-risk pediatric patients within the Colombian healthcare system , Biomedica: Vol. 35 No. 4 (2015)
- Yazmin Rocío Arias, Karime Osorio-Arango, Brayan Bayona, Guadalupe Ercilla, Mauricio Beltrán-Durán, Determination of HLA-A, -B and -DRB1 polymorphism in brain dead organ donors representative of the Colombian general population, 2007-2014 , Biomedica: Vol. 37 No. 2 (2017)
- Lina Echeverri-Toro, Andrés Arango, Sigifredo Ospina, Carlos Agudelo, Bordetella bronchiseptica recurrent bacteraemia in a patient with bone marrow transplantation , Biomedica: Vol. 35 No. 3 (2015)
- Fiona Xacur-García, Rodrigo Díaz-Novelo, Linnete Herrera-David, Paulina Moreno-Arjona, Nina Méndez-Domínguez, Manifestaciones clínicas y evolución a largo plazo de tres casos de rosácea ocular atendidos en un hospital de alta especialidad del sureste de México , Biomedica: Vol. 40 No. 3 (2020)
| Article metrics | |
|---|---|
| Abstract views | |
| Galley vies | |
| PDF Views | |
| HTML views | |
| Other views | |
